Literature DB >> 25697036

[Updated treatment algorithm of pulmonary arterial hypertension].

Nazzareno Galiè, Paul A Corris, Adaani Frost, Reda E Girgis, John Granton, Zhi Cheng Jing, Walter Klepetko, Michael D McGoon, Vallerie V McLaughlin, Ioana R Preston, Lewis J Rubin, Julio Sandoval, Werner Seeger, Anne Keogh.   

Abstract

The demands on a pulmonary arterial hypertension (PAH) treatment algorithm are multiple and in some ways conflicting. The treatment algorithm usually includes different types of recommendations with varying degrees of scientific evidence. In addition, the algorithm is required to be comprehensive but not too complex, informative yet simple and straightforward. The type of information in the treatment algorithm are heterogeneous including clinical, hemodynamic, medical, interventional, pharmacological and regulatory recommendations. Stakeholders (or users) including physicians from various specialties and with variable expertise in PAH nurses, patients and patients' associations, healthcare providers, regulatory agencies and industry are often interested in the PAH treatment algorithm for different reasons. These are the considerable challenges faced when proposing appropriate updates to the current evidence-based treatment algorithm.The current treatment algorithm may be divided into 3 main areas: 1) general measures, supportive therapy referral strategy, acute vasoreactivity testing and chronic treatment with calcium channel blockers; 2) initial therapy with approved PAH drugs; and 3) clinical response to the initial therapy, combination therapy, balloon atrial septostomy and lung transplantation. All three sections will be revisited highlighting information newly available in the past 5 years and proposing updates where appropriate. The European Society of Cardiology grades of recommendation and levels of evidence will be adopted to rank the proposed treatments. (J Am Coll Cardiol 2013;62:D60-72) ©2013 by the American College of Cardiology Foundation.

Entities:  

Year:  2014        PMID: 25697036

Source DB:  PubMed          Journal:  Turk Kardiyol Dern Ars        ISSN: 1016-5169


  2 in total

1.  EP4 Agonist L-902,688 Suppresses EndMT and Attenuates Right Ventricular Cardiac Fibrosis in Experimental Pulmonary Arterial Hypertension.

Authors:  Ying-Ju Lai; I-Chen Chen; Hsin-Hsien Li; Chung-Chi Huang
Journal:  Int J Mol Sci       Date:  2018-03-03       Impact factor: 5.923

2.  Abnormal pulmonary artery systolic pressure response after exercise in systemic sclerosis patients: A PRISMA-compliant meta-analysis.

Authors:  Song Yang; Jing Wu; Si Lei; Rong Song; Ye-Yu Cai; Shang-Jie Wu
Journal:  Medicine (Baltimore)       Date:  2019-02       Impact factor: 1.817

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.